Upfront CART-BCMA with or without huCART19 in High-risk Multiple Myeloma

Issue: February 2020

ByDrew Amorosi

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Phase 1, interventional, open-label study to assess the safety and pharmacodynamics of CART-BCMA, with or without huCART19, for patients responding to first- or second-line therapy for high-risk multiple myeloma.